Early warning and prevention of pneumonia in acute leukemia by patient education, spirometry, and positive expiratory pressure: A randomized controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Early warning and prevention of pneumonia in acute leukemia by patient education, spirometry, and positive expiratory pressure : A randomized controlled trial. / Møller, Tom; Moser, Claus; Adamsen, Lis; Rugaard, Grith; Jarden, Mary; Bøtcher, Tina S; Wiedenbein, Liza Kerstin; Kjeldsen, Lars.

In: American Journal of Hematology, Vol. 91, No. 3, 03.2016, p. 271-6.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Møller, T, Moser, C, Adamsen, L, Rugaard, G, Jarden, M, Bøtcher, TS, Wiedenbein, LK & Kjeldsen, L 2016, 'Early warning and prevention of pneumonia in acute leukemia by patient education, spirometry, and positive expiratory pressure: A randomized controlled trial', American Journal of Hematology, vol. 91, no. 3, pp. 271-6. https://doi.org/10.1002/ajh.24262

APA

Møller, T., Moser, C., Adamsen, L., Rugaard, G., Jarden, M., Bøtcher, T. S., ... Kjeldsen, L. (2016). Early warning and prevention of pneumonia in acute leukemia by patient education, spirometry, and positive expiratory pressure: A randomized controlled trial. American Journal of Hematology, 91(3), 271-6. https://doi.org/10.1002/ajh.24262

Vancouver

Møller T, Moser C, Adamsen L, Rugaard G, Jarden M, Bøtcher TS et al. Early warning and prevention of pneumonia in acute leukemia by patient education, spirometry, and positive expiratory pressure: A randomized controlled trial. American Journal of Hematology. 2016 Mar;91(3):271-6. https://doi.org/10.1002/ajh.24262

Author

Møller, Tom ; Moser, Claus ; Adamsen, Lis ; Rugaard, Grith ; Jarden, Mary ; Bøtcher, Tina S ; Wiedenbein, Liza Kerstin ; Kjeldsen, Lars. / Early warning and prevention of pneumonia in acute leukemia by patient education, spirometry, and positive expiratory pressure : A randomized controlled trial. In: American Journal of Hematology. 2016 ; Vol. 91, No. 3. pp. 271-6.

Bibtex

@article{5c0e2d424265490f878709b693028d53,
title = "Early warning and prevention of pneumonia in acute leukemia by patient education, spirometry, and positive expiratory pressure: A randomized controlled trial",
abstract = "Long-lasting neutropenia associated with acute myeloid leukemia (AML) and its treatment gives rise to a high risk of pneumonia. The use of broad-spectrum antibiotic prophylaxis during outpatient management has not completely protected patients against admission due to infections and neutropenic fever, emphasizing the need to approach infection protection with complementary efforts. In a randomized controlled design, we examined the applicability of patient-performed daily spirometry [forced expiratory volume in one second (FEV1)] as an early warning tool and explored the effectiveness of positive expiratory pressure (PEP) in preventing pneumonia among 80 AML patients. Twenty-five incidences of pneumonia were detected among 23 patients (6 interventions, 17 controls), giving a prevalence of 28.75{\%} during 5420 days of observation. We found a significant difference in incidence between intervention versus control group (2.17 per 1000 days vs. 6.52 per 1000 days, P = 0.021, respectively). A cross point at 80-76{\%} of the personal FEV1 reference value showed high sensitivity and specificity on pneumonia development. Our data demonstrate the feasibility of educating AML patients in their continuous daily measurement of FEV1 and use of PEP. Daily measures of FEV1 may be an important early warning tool for assessment of pulmonary deterioration during critical phases of neutropenia. We suggest that strategic patient education in the use of spirometry and PEP should be part of standard of care for AML patients undergoing induction chemotherapy. Am. J. Hematol. 91:271-276, 2016. {\circledC} 2015 The Authors. American Journal of Hematology Published by Wiley Periodicals, Inc.",
author = "Tom M{\o}ller and Claus Moser and Lis Adamsen and Grith Rugaard and Mary Jarden and B{\o}tcher, {Tina S} and Wiedenbein, {Liza Kerstin} and Lars Kjeldsen",
note = "{\circledC} 2015 The Authors. American Journal of Hematology Published by Wiley Periodicals, Inc.",
year = "2016",
month = "3",
doi = "10.1002/ajh.24262",
language = "English",
volume = "91",
pages = "271--6",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "JohnWiley & Sons, Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Early warning and prevention of pneumonia in acute leukemia by patient education, spirometry, and positive expiratory pressure

T2 - A randomized controlled trial

AU - Møller, Tom

AU - Moser, Claus

AU - Adamsen, Lis

AU - Rugaard, Grith

AU - Jarden, Mary

AU - Bøtcher, Tina S

AU - Wiedenbein, Liza Kerstin

AU - Kjeldsen, Lars

N1 - © 2015 The Authors. American Journal of Hematology Published by Wiley Periodicals, Inc.

PY - 2016/3

Y1 - 2016/3

N2 - Long-lasting neutropenia associated with acute myeloid leukemia (AML) and its treatment gives rise to a high risk of pneumonia. The use of broad-spectrum antibiotic prophylaxis during outpatient management has not completely protected patients against admission due to infections and neutropenic fever, emphasizing the need to approach infection protection with complementary efforts. In a randomized controlled design, we examined the applicability of patient-performed daily spirometry [forced expiratory volume in one second (FEV1)] as an early warning tool and explored the effectiveness of positive expiratory pressure (PEP) in preventing pneumonia among 80 AML patients. Twenty-five incidences of pneumonia were detected among 23 patients (6 interventions, 17 controls), giving a prevalence of 28.75% during 5420 days of observation. We found a significant difference in incidence between intervention versus control group (2.17 per 1000 days vs. 6.52 per 1000 days, P = 0.021, respectively). A cross point at 80-76% of the personal FEV1 reference value showed high sensitivity and specificity on pneumonia development. Our data demonstrate the feasibility of educating AML patients in their continuous daily measurement of FEV1 and use of PEP. Daily measures of FEV1 may be an important early warning tool for assessment of pulmonary deterioration during critical phases of neutropenia. We suggest that strategic patient education in the use of spirometry and PEP should be part of standard of care for AML patients undergoing induction chemotherapy. Am. J. Hematol. 91:271-276, 2016. © 2015 The Authors. American Journal of Hematology Published by Wiley Periodicals, Inc.

AB - Long-lasting neutropenia associated with acute myeloid leukemia (AML) and its treatment gives rise to a high risk of pneumonia. The use of broad-spectrum antibiotic prophylaxis during outpatient management has not completely protected patients against admission due to infections and neutropenic fever, emphasizing the need to approach infection protection with complementary efforts. In a randomized controlled design, we examined the applicability of patient-performed daily spirometry [forced expiratory volume in one second (FEV1)] as an early warning tool and explored the effectiveness of positive expiratory pressure (PEP) in preventing pneumonia among 80 AML patients. Twenty-five incidences of pneumonia were detected among 23 patients (6 interventions, 17 controls), giving a prevalence of 28.75% during 5420 days of observation. We found a significant difference in incidence between intervention versus control group (2.17 per 1000 days vs. 6.52 per 1000 days, P = 0.021, respectively). A cross point at 80-76% of the personal FEV1 reference value showed high sensitivity and specificity on pneumonia development. Our data demonstrate the feasibility of educating AML patients in their continuous daily measurement of FEV1 and use of PEP. Daily measures of FEV1 may be an important early warning tool for assessment of pulmonary deterioration during critical phases of neutropenia. We suggest that strategic patient education in the use of spirometry and PEP should be part of standard of care for AML patients undergoing induction chemotherapy. Am. J. Hematol. 91:271-276, 2016. © 2015 The Authors. American Journal of Hematology Published by Wiley Periodicals, Inc.

U2 - 10.1002/ajh.24262

DO - 10.1002/ajh.24262

M3 - Journal article

VL - 91

SP - 271

EP - 276

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -

ID: 162597011